Search

BackgroundPostdischarge nausea and vomiting after ambulatory surgery is a common problem that is not adequately addressed in current practice. This prospective, randomized, double-blind, parallel-group, placebo-controlled study was designed to test the hypothesis that oral olanzapine is superior to placebo at preventing postdischarge nausea and vomiting.MethodsIn a single-center, double-blind, randomized, placebo-controlled trial, the authors compared a single preoperative dose of olanzapine 10 mg to placebo, in adult female patients 50 years old or less, undergoing ambulatory gynecologic or plastic surgery with general anesthesia. All patients received standard antiemetic prophylaxis with dexamethasone and ondansetron. The primary composite outcome was nausea and/or vomiting in the 24 h after discharge. Secondary outcomes included severe nausea, vomiting, and side effects.ResultsA total of 140 patients were randomized and evaluable. The primary outcome occurred in 26 of 69 patients (38%) in the placebo group and in 10 of 71 patients (14%) in the olanzapine group (relative risk, 0.37; 95% CI, 0.20 to 0.72; P = 0.003). Severe nausea occurred in 14 patients (20%) in the placebo group and 4 patients (6%) in the olanzapine group (relative risk, 0.28; 95% CI, 0.10 to 0.80). Vomiting occurred in eight patients (12%) in the placebo group and two patients (3%) in the olanzapine group (relative risk, 0.24; 95% CI, 0.05 to 1.10). The median score for sedation (scale 0 to 10, with 10 being highest) in the 24 h after discharge was 4 (interquartile range, 2 to 7) in the placebo group and 6 (interquartile range, 3 to 8) in the olanzapine group (P = 0.023).ConclusionsWhen combined with ondansetron and dexamethasone, the addition of olanzapine relative to placebo decreased the risk of nausea and/or vomiting in the 24 h after discharge from ambulatory surgery by about 60% with a slight increase in reported sedation.Editor’s PerspectiveWhat We Already Know about This TopicWhat This Article Tells Us That Is New

SPRITE, the first NASA-funded 12U CubeSat for astrophysics science, will use an ultraviolet light spectrograph with a photon-counting microchannel plate detector to provide spatial and spectral data on the light observed from low-redshift galaxies, active galactic nuclei, and shocked emission features of supernova remnants in the 1000Å − 1750Å bandpass. This proceedings describes recent progress on the design, implementation, and experimental evaluation of SPRITE’s electrical subsystems, particularly the high voltage power supply required to drive the microchannel plate detector. Measured experimental results for the commercial high voltage power supply module and the electronics board designed and built to control it are presented and discussed. The average voltage and voltage ripple of the high voltage power supply output when driving a resistive load that simulates the load anticipated on orbit due to the detector and a parallel voltage divider are presented. Planned revisions to the SPRITE electronics design are discussed, including modifications to be made to the high voltage power supply control board and the addition of an electronics board to handle all the interfaces between the command and data handling subsystem and the instrument electrical subsystems. SPRITE is planned to launch in early 2023 and will provide on-orbit data for the microchannel plate detector and other technologies onboard that are candidates for use on future large missions.